Use of nonsteroidal antiinflammatory drugs and risk of colon cancer in a population-based, case-control study of African Americans and Whites

American Journal of Epidemiology

Volumn 162, Issue 6, 2005, Pages 548-558

  Sansbury, Leah B ^a   Millikan, Robert C ^b,c   Schroeder, Jane C ^b,c   Moorman, Patricia G ^d   North, Kari E ^b   Sandler, Robert S ^b,c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b IL   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

African Americans; Anti inflammatory agents, non steroidal; Case control studies; Colonic neoplasms; European Continental Ancestry Group

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT;

CANCER; COMPARATIVE STUDY; DRUG PRESCRIBING; ETHNICITY; RISK FACTOR;

ADULT; AFRICAN AMERICAN; AGED; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CALCULATION; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CASE CONTROL STUDY; CHEMOPROPHYLAXIS; COLON CARCINOMA; CONFIDENCE INTERVAL; CONTROLLED STUDY; ETHNIC GROUP; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; POPULATION RISK; SAMPLE SIZE; SEX DIFFERENCE; STATISTICAL ANALYSIS;

ADENOCARCINOMA; ADULT; AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CASE-CONTROL STUDIES; COLONIC NEOPLASMS; CONFOUNDING FACTORS (EPIDEMIOLOGY); EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; LIFE STYLE; MALE; MIDDLE AGED; NORTH CAROLINA;

NORTH AMERICA; UNITED STATES; WESTERN HEMISPHERE; WORLD;

EID: 24344494442     PISSN: 00029262     EISSN: None     Source Type: Journal    
DOI: 10.1093/aje/kwi248     Document Type: Article

References (62)

1. American Cancer Society. Cancer facts and figures, 2003. Atlanta, GA: American Cancer Society, 2003. (ACS publication no. 5008.03).
2. Ries LAG, Eisner MP, Kosary CL, et al, eds. SEER cancer statistics review, 1975-2001. Bethesda, MD: National Cancer Institute, 2004. (http://seer.cancer.gov/csr/1975_2001/).
3. Swan J, Breen N, Coates RJ, et al. Progress in cancer screening practices in the United States: results from the 2000 National Health Interview Survey. Cancer 2003;97:1528-40.
4. Collet JP, Sharpe C, Belzile E, et al. Colorectal cancer prevention by non-steroidal anti-inflammatory drugs: effects of dosage and timing. Br J Cancer 1999;81:62-8.
5. Garcia-Rodriguez LA, Huerta-Alvarez C. Reduced risk of colorectal cancer among long-term users of aspirin and non-aspirin nonsteroidal antiinflammatory drugs. Epidemiology 2001;12:88-93.
6. Muscat JE, Stellman SD, Wynder EL. Nonsteriodal antiinflammatory drugs and colorectal cancer. Cancer 1994;74:1847-54.
7. Peleg II, Lubin MF, Cotsonis GA, et al. Long-term use of nonsteroidal antiinflammatory drugs and other chemopreventors and risk of subsequent colorectal neoplasia. Dig Dis Sci 1996;41:1319-26.
8. Peleg II, Maibach HT, Brown SH, et al. Aspirin use and non-steroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. Arch Intern Med 1994;154:394-9.
9. Suh O, Mettlin C, Petrelli NJ. Aspirin use, cancer, and polyps of the large bowel. Cancer 1993;72:1171-7.
10. Sturmer T, Glynn RJ, Lee IM, et al. Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians' Health Study. Ann Intern Med 1998;128:713-20.
11. Smalley W, Ray WA, Daugherty J, et al. Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: a population-based study. Arch Intern Med 1999;159:161-6.
12. La Vecchia C, Negri E, Franceschi S, et al. Aspirin and colorectal cancer. Br J Cancer 1997;76:675-7.
13. Logan RF, Little J, Hawtin PG, et al. Effect of aspirin and non-steroidal anti-inflammatory drugs on colorectal adenomas: case-control study of subjects participating in the Nottingham faecal occult blood screening programme. BMJ 1993;307:285-9.
14. Giovannucci E, Rimm EB, Stampfer MJ, et al. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994;121:241-6.
15. Giovannucci E, Egan KM, Hunter DJ, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995;333:609-14.
16. Rosenberg L, Palmer FR, Zauber AG, et al. A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst 1991;83:355-8.
17. Rosenberg L, Louik C, Shapiro S. Nonsteroidal anti-inflammatory drug use and reduced risk of large bowel carcinoma. Cancer 1998;82:2326-33.
18. Shaheen NJ, Straus WL, Sandler RS. Chemoprevention of gastrointestinal malignancies with nonsteroidal antiinflammatory drugs. Cancer 2002;94:950-63.
19. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002;94:252-66.
20. Thun MJ, Namboodiri MM, Calle EE, et al. Aspirin use and risk of fatal cancer. Cancer Res 1993;53:1322-7.
21. Friedman GD, Coates AO, Potter JD, et al. Drugs and colon cancer. Pharmacoepidemiol Drug Saf 1998;7:99-106.
22. Krishnan K, Ruffin MT 4th, Brenner DE. Chemoprevention for colorectal cancer. Crit Rev Oncol Hematol 2000;33:199-219.
23. Steele VE, Hawk ET, Viner JL, et al. Mechanisms and applications of non-steroidal anti-inflammatory drugs in the chemoprevention of cancer. Mutat Res 2003;523-524:137-44.
24. Vane JR, Botting RM. Mechanism of action of nonsteroidal anti-inflammatory drugs. Am J Med 1998;104:2S-8S.
25. Coogan PF, Rosenberg L, Louik C, et al. NSAIDs and risk of colorectal cancer according to presence or absence of family history of the disease. Cancer Causes Control 2000;11:249-55.
26. Kune GA, Kune S, Watson LF. Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res 1988;48:4399-404.
27. Sorensen HT, Friis S, Norgard B, et al. Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. Br J Cancer 2003;88:1687-92.
28. Baron JA, Cole B, Sandier RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348:891-9.
29. Langman MJ, Cheng KK, Gilman EA, et al. Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ 2000;320:1642-6.
30. London SJ, Daly AK, Leathart JB, et al. Lung cancer risk in relation to the CYP2C9*1/CYP2C9*2 genetic polymorphism among African-Americans and Caucasians in Los Angeles County, California. Pharmacogenetics 1996;6:527-33.
31. Bigler J, Whitton J, Lampe JW, et al. CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk. Cancer Res 2001;61:3566-9.
32. Glue P, Clement RP. Cytochrome P450 enzymes and drug metabolism - basic concepts and methods of assessment. Cell Mol Neurobiol 1999;19:309-23.
33. Guengerich FP. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 1999;39:1-17.
34. Lin HJ, Lakkides KM, Keku T, et al. Prostaglandin H synthase 2 variant (Val511Ala) in African Americans may reduce the risk for colorectal neoplasia. Cancer Epidemiol Biomarkers Prev 2002;11:1305-15.
35. Aldrich TE, Vann D, Moorman PG, et al. Rapid reporting of cancer incidence in a population-based study of breast cancer: one constructive use of a central cancer registry. Breast Cancer Res Treat 1995;35:61-4.
36. Block G, Hartman AM, Dresser CM, et al. A data-based approach to diet questionnaire design and testing. Am J Epidemiol 1986;124:453-69.
37. Ouellet M, Percival MD. Mechanism of acetaminophen inhibition of cyclooxygenase isoforms. Arch Biochem Biophys 2001;387:273-80.
38. Hsieh CC, Maisonneuve P, Boyle P, et al. Analysis of quantitative data by quantiles in epidemiologic studies: classification according to cases, noncases, or all subjects? Epidemiology 1991;2:137-40.
39. Willett W, Stampfer MJ. Total energy intake: implications for epidemiologic analysis. Am J Epidemiol 1986;124:17-27.
40. The practical guide: identification, evaluation, and treatment of overweight and obesity in adults. Bethesda, MD: National Institutes of Health, 2000. (http://www.nhlbi.nih.gov/guidelines/obesity/prctgd_c.pdf) (NIH publication no. 00-4084).
41. Ainsworth BE, Haskell WL, Whitt MC, et al. Compendium of physical activities: an update of activity codes and MET intensities. Med Sci Sports Exerc 2000;32(suppl):S498-504.
42. Richardson MT, Ainsworth BE, Jacobs DR, et al. Validation of the Stanford 7-day recall to assess habitual physical activity. Ann Epidemiol 2001;11:145-53.
43. Greenland S, Pearl J, Robbins JM. Causal diagrams for epidemiological research. Epidemiology 1999;10:37-48.
44. Rothman KJ, Greenland S. Modern epidemiology. Philadelphia, PA: Lippincott-Raven Publishers, 1998.
45. Stokes ME, Davis CS, Koch GG. Categorical data analysis using the SAS system. Cary, NC: SAS Institute, Inc, 2000.
46. Hosmer DW, Lemeshow S. Applied logistic regression. New York, NY: John Wiley & Sons, Inc, 1989.
47. Weir HK, Thun MJ, Hankey BF, et al. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 2003;95:1276-99.
48. Ries LA, Wingo PA, Miller DS, et al. The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer. Cancer 2000;88:2398-424.
49. Devesa SS, Grauman DG, Blot WJ, et al. Atlas of cancer mortality in the United States, 1950-94. Washington, DC: National Institutes of Health, 1999.
50. Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 1994;5:138-46.
51. West SL, Savitz DA, Koch G, et al. Recall accuracy for prescription medications: self-report compared with database information. Am J Epidemiol 1995;142:1103-12.
52. Grodstein F, Newcomb PA, Stampfer MJ. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med 1999;106:574-82.
53. Fernandez E, Gallus S, Bosetti C, et al. Hormone replacement therapy and cancer risk: a systemic analysis from a network of case-control studies. Int J Cancer 2003;105:408-12.
54. Woodson K, Lanza E, Tangrea JA, et al. Hormone replacement therapy and colorectal adenoma recurrence among women in the Polyp Prevention Trial. J Natl Cancer Inst 2001;93:1799-805.
55. Distler P, Holt PR. Are right- and left-sided colon neoplasms distinct tumors? Dig Dis 1997;15:302-11.
56. Iacopetta B. Are there two sides to colorectal cancer? Int J Cancer 2002;101:403-8.
57. Paganini-Hill A, Chao A, Ross RK, et al. Aspirin use and chronic diseases: a cohort study of the elderly. BMJ 1989;299:1247-50.
58. Moorman PG, Newman B, Millikan RC, et al. Participation rates in a case-control study: the impact of age, race, and race of interviewer. Ann Epidemiol 1999;9:188-95.
59. Dosemeci M, Wacholder S, Lubin JH. Does nondifferential misclassification of exposure always bias a true effect toward the null value? Am J Epidemiol 1990;132:746-8.
60. Chan AT. Aspirin, non-steroidal anti-inflammatory drugs and colorectal neoplasia: future challenges in chemoprevention. Cancer Causes Control 2003;14:143-8.
61. Jackson LM, Hawkey CJ. NSAIDs and the GI tract - potential hazards and benefits. Apoptosis 1999;4:397-402.
62. Vainio H, Morgan G, Elwood P. The public health potential of aspirin. Pharmacol Toxicol 2002;91:49-50.